Deslorelin is a synthetic gonadotropin-releasing hormone (GnRH) analog with a potency approximately 30–150 times that of natural GnRH. As a GnRH agonist, it initially and briefly stimulates the pituitary gland to release gonadotropins (the "flare-up" effect). Subsequently, through sustained agonistic action, it leads to pituitary desensitization and downregulation of GnRH receptors, thereby inhibiting the secretion of gonadotropins (LH, FSH) and ultimately suppressing the production of sex steroid hormones.
Dulaglutide is a long‑acting glucagon‑like peptide‑1 (GLP‑1) receptor agonist. It mimics the action of endogenous GLP‑1, stimulating glucose‑dependent insulin secretion, suppressing glucagon release, delaying gastric emptying, and promoting satiety. These effects collectively contribute to improved glycemic control, reduced postprandial glucose levels, and weight management support in research models.
For research purposes, dulaglutide dosing is typically based on model specification (in vitro or in vivo) and experimental design. In preclinical rodent studies, doses often range from 0.1 mg/kg to 1 mg/kg administered subcutaneously once weekly. For larger animal models, dose adjustments are made according to body weight and pharmacodynamic response. Dulaglutide’s extended half‑life supports once‑weekly dosing in both preclinical and translational studies. Researchers should follow institutional guidelines and safety protocols when handling and dosing.
Dulaglutide is protected by multiple granted patents covering composition, formulation, and therapeutic use. Key patents include:
These patents provide broad protection for GLP‑1 based peptide therapeutics, including dulaglutide analog structures, method of use claims for glycemic control, and related formulation technology in major markets.
Dulaglutide supplied by ThinHeal is manufactured in a cGMP‑compliant facility, with rigorous quality control at each production stage. Each batch undergoes comprehensive testing for identity, purity, potency, and stability in accordance with international standards. Quality documentation, including Certificate of Analysis (CoA), is provided upon request to support regulatory or scientific use.
ThinHeal is committed to providing dependable service and seamless logistics throughout the product lifecycle. Before shipment, all products are quality‑verified and labeled with batch information. We offer comprehensive shipping solutions, including cold‑chain packaging tailored to destination and transit duration, with tracking support available. After delivery, our team is available to assist with storage conditions, technical questions, and follow‑up documentation to support research continuity.